At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
VVOS Vivos Therapeutics
Pre-Market Trading 11-05 07:30:59 EST
2.69
+0.01
+0.37%
High2.75Low2.61Vol54.34K
Open2.70D1 Closing2.68Amplitude5.22%
Mkt Cap12.82MTradable Cap12.28MTotal Shares4.77M
T/O146.68KT/O Rate1.19%Tradable Shares4.56M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
Vivos Therapeutics Granted CPT® Coverage and Reimbursement Codes for All Vivos CARE Oral Medical Devices From American Medical Association
GlobeNewswire  ·  10-08
Vivos Therapeutics Granted CPT® Coverage and Reimbursement Codes for All Vivos CARE Oral Medical Devices From American Medical Association
Dow Jumps Over 500 Points; FactSet Research Posts Upbeat Earnings
Benzinga  ·  09-20
Dow Jumps Over 500 Points; FactSet Research Posts Upbeat Earnings
Vivos Therapeutics Shares Drop 27% After Pricing of Common Stock Offering
Dow Jones  ·  09-19
Vivos Therapeutics Shares Drop 27% After Pricing of Common Stock Offering
Vivos Therapeutics Prices $4.3 Million Common Stock Offering; Shares Fall Pre-Bell
MT Newswires Live  ·  09-19
Vivos Therapeutics Prices $4.3 Million Common Stock Offering; Shares Fall Pre-Bell
Vivos Therapeutics announces $4.3M registered direct offering of common stock
seekingalpha  ·  09-19
Vivos Therapeutics announces $4.3M registered direct offering of common stock
BRIEF-Vivos Therapeutics Prices $4.3 Mln Registered Direct Offering Of Common Stock
Reuters  ·  09-19
BRIEF-Vivos Therapeutics Prices $4.3 Mln Registered Direct Offering Of Common Stock
Vivos Therapeutics Announces Pricing of $4.3 Million Registered Direct Offering of Common Stock Priced at-the-Market Under Nasdaq Rules
THOMSON REUTERS  ·  09-19
Vivos Therapeutics Announces Pricing of $4.3 Million Registered Direct Offering of Common Stock Priced at-the-Market Under Nasdaq Rules
Vivos Therapeutics Inc - to Issue 1,363,812 Shares at $3.15 Each
THOMSON REUTERS  ·  09-19
Vivos Therapeutics Inc - to Issue 1,363,812 Shares at $3.15 Each
Vivos Therapeutics Announces Pricing of $4.3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
GlobeNewswire  ·  09-19
Vivos Therapeutics Announces Pricing of $4.3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
Vivos surges on FDA nod for pediatric sleep apnea device
seekingalpha  ·  09-19
Vivos surges on FDA nod for pediatric sleep apnea device
BUZZ-Vivos Therapeutics rises on FDA approval for pediatric sleep apnea device
Reuters  ·  09-18
BUZZ-Vivos Therapeutics rises on FDA approval for pediatric sleep apnea device
Vivos Therapeutics Says It Is Poised To Disrupt Pediatric Sleep Apnea Market, Secures FDA Approval For DNA Appliance To Treat Snoring In Children
Benzinga  ·  09-18
Vivos Therapeutics Says It Is Poised To Disrupt Pediatric Sleep Apnea Market, Secures FDA Approval For DNA Appliance To Treat Snoring In Children
Vivos Therapeutics Shares Rally on FDA Clearance for Pediatric Sleep Apnea Treatment
Dow Jones  ·  09-18
Vivos Therapeutics Shares Rally on FDA Clearance for Pediatric Sleep Apnea Treatment
Vivos Therapeutics' Sleep Disorder Treatment Device Receives FDA Clearance
MT Newswires Live  ·  09-18
Vivos Therapeutics' Sleep Disorder Treatment Device Receives FDA Clearance
Vivos Therapeutics Receives Groundbreaking FDA 510(K) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring
THOMSON REUTERS  ·  09-18
Vivos Therapeutics Receives Groundbreaking FDA 510(K) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring
Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring
GlobeNewswire  ·  09-18
Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring
Vivos Therapeutics Enhances Incentives and Executive Pay Structure
TIPRANKS  ·  09-13
Vivos Therapeutics Enhances Incentives and Executive Pay Structure
Vivos Therapeutics, Inc.'s (NASDAQ:VVOS) Shares Leap 41% Yet They're Still Not Telling The Full Story
Simply Wall St.  ·  09-10
Vivos Therapeutics, Inc.'s (NASDAQ:VVOS) Shares Leap 41% Yet They're Still Not Telling The Full Story
Vivos Therapeutics Is Maintained at Buy by Ascendiant Capital
Dow Jones  ·  08-20
Vivos Therapeutics Is Maintained at Buy by Ascendiant Capital
Vivos Therapeutics GAAP EPS of -$0.60, revenue of $4.1M
seekingalpha  ·  08-16
Vivos Therapeutics GAAP EPS of -$0.60, revenue of $4.1M

Introduction

Company Name.
Vivos Therapeutics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was founded in 2016 and is based in Littleton, Colorado.
Issue price:
--